Can antiviral drugs prevent long COVID if taken early?

Do antivirals actually prevent long COVID? Here's what the numbers say.

Yes, the strongest evidence we have suggests that taking antiviral drugs early in a COVID-19 infection can reduce your risk of developing long COVID. The most comprehensive analysis, a meta-analysis of six studies involving over 3.3 million people, found that those who received early antiviral treatment had a 27.5% lower chance of developing post-acute sequelae of COVID-19 (PASC) compared to those who got supportive care only [1]. That's a substantial reduction, though it doesn't eliminate the risk entirely.

A separate study of 649 high-risk outpatients in Italy backs this up with a more dramatic figure: patients treated with antivirals were about 57% less likely to report any persistent symptoms at the three-month mark (odds ratio of 0.43) compared to untreated patients [2]. The same study also found that early treatment with monoclonal antibodies or antivirals reduced the risk of hospitalization or death at one and three months [2]. So the benefit isn't just about feeling better—it's about avoiding serious outcomes.

How do antivirals help, and who should consider them?

The leading theory is that antivirals work by reducing the amount of virus in your body early in the infection, which limits the severe tissue damage and inflammation that can trigger long-term symptoms. A mathematical modeling study suggests that while antivirals may not completely prevent the virus from lingering in some people, they are effective because they prevent the acute damage that sets the stage for long COVID [5]. This means the drugs are most useful when taken as soon as possible after symptoms start.

The benefits appear strongest for people at higher risk of severe COVID-19. In the Italian study, patients were older and had conditions like heart disease or obesity [2]. A real-world study in China of patients who developed lung scarring after COVID found that those who received small-molecule antivirals during their hospital stay had a significantly lower one-year readmission rate (46% vs. 64% for those not treated) [3]. If you're in a high-risk group, early antiviral treatment is a particularly important option to discuss with your doctor.

What are the limitations? Not a magic bullet, but a strong tool.

While the evidence is encouraging, it's important to understand the limits. The studies are mostly observational, not randomized controlled trials, which means other factors (like healthier people being more likely to seek treatment) could influence the results. The meta-analysis notes that the studies included were observational cohorts [1], so we can't say for certain that antivirals cause the reduced risk—only that they are strongly associated with it.

Also, the benefit is not universal. The modeling study suggests that for people who already have persistent infection, antivirals alone may not clear the virus, and combining them with vaccination might be more effective [5]. And while the reduction in risk is real, it's not 100%—many people who take antivirals still develop long COVID. The drugs are a powerful preventive measure, but they are not a guarantee.

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2023 to 2026, 3 from 2024 or later, 3 in Q1 journals, collectively cited 60 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 59 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions